Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | BMP1 | P13497 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012258 | 1.00 | TAS2R14 (0.54) | TAS2R14CXCR3PTGESTAS2R8MEP1B | |
| SCHEMBL29691981 | 0.84 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8BMP1 | |
| SCHEMBL29757354 | 0.84 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8BMP1 | |
| SCHEMBL29691491 | 0.83 | TAS2R14 (0.58) | TAS2R14CXCR3PTGESTAS2R8MEP1B | |
| SCHEMBL23012238 | 0.83 | TAS2R14 (0.58) | TAS2R14CXCR3PTGESTAS2R8MEP1B | |
| SCHEMBL29691348 | 0.83 | TAS2R14 (0.50) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL23012843 | 0.83 | TAS2R14 (0.50) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL23851055 | 0.81 | TAS2R14 (0.56) | TAS2R14CXCR3PTGESTAS2R8 | |
| SCHEMBL23012381 | 0.78 | TAS2R14 (0.53) | TAS2R14CXCR3PTGESTAS2R8MEP1B | |
| SCHEMBL29757359 | 0.78 | TAS2R14 (0.45) | TAS2R14CXCR3PTGESTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555609-A | Macrocyclic sulfonamide derivatives useful as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-05-27 | — | — | CN | disclosed |